<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143778</url>
  </required_header>
  <id_info>
    <org_study_id>CSPH-EX-4014</org_study_id>
    <secondary_id>2014-002037-59</secondary_id>
    <nct_id>NCT02143778</nct_id>
  </id_info>
  <brief_title>Assessing Portal Hypertension With Methacetin Breath Test</brief_title>
  <official_title>Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be used to train an algorithm using Methacetin breath test (MBT) measures and
      to select a cut-off to determine presence or absence of Clinically Significant Portal
      Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSPH</measure>
    <time_frame>1 hour</time_frame>
    <description>Clinically significant portal hypertension , defined as Hepatic Venous Pressure Gradient (HVPG)&gt;=10mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HVPG&gt;=12</measure>
    <time_frame>1 hour</time_frame>
    <description>Hepatic Venous Pressure Gradient greater than 12 is an indicator of bleeding varices</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Patients With Compensated Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Compensated cirrhotic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Methacetin Breath Test</intervention_name>
    <description>13C labelled methacetin solution for breath test monitoring</description>
    <arm_group_label>Compensated cirrhotic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men or women (&gt;18 years of age)

          -  Known chronic liver disease with cirrhosis

          -  Europe: Indicated to undergo HVPG testing

          -  US: Consented for HVPG

          -  For patients treated with beta blockers: They have to be on a stable dose for at least
             6 weeks prior to any study related tasks

          -  For patients who stopped their treatment with beta blockers: Their last dose should be
             at least 6 weeks prior to any study related tasks

        Exclusion Criteria:

          -  Decompensated cirrhosis as clinically defined by the presence of ascites, hepatic
             encephalopathy, variceal bleeding or hepatorenal syndrome

          -  Renal failure (creatinine &gt; 2.5 mg/dl)

          -  Known acute renal tubular disease Known hypotension (Systolic Pressure &lt;100mmHg)

          -  Hypocoagulablity defined as PT &gt;6 and INR &gt;2.3.

          -  Congestive heart failure (assessed clinically as NIHA &gt;2)

          -  Known pulmonary hypertension (right ventricular systolic pressure &gt; 45 mm Hg)

          -  Uncontrolled diabetes mellitus (HBA1C &gt;9.5gr%)

          -  Concurrent prednisone or immunosuppressive treatment, if therapy and/or response to
             treatment are not stable for at least 3 months.

          -  Documented or suspected hepatocellular carcinoma

          -  Gastric bypass surgery or extensive small bowel resection

          -  Total parenteral nutrition

          -  Any organ transplant recipient

          -  Pregnant or breast feeding

          -  Allergy to acetaminophen and/or other related medications

          -  Documented drug-related concurrent hepatotoxicity or drug-related silent steatosis or
             drug-related fibrosis (e.g. amiodarone, methotrexate and tamoxifen)

          -  Uncontrolled malabsorption or diarrhea

          -  Documented non-cirrhotic PHT, partial / complete portal venous occlusion, hepatic
             venous occlusion, previous PHT surgery, or placement of a transjugular intrahepatic
             portosystemic shunt (TIPS)

          -  Primary or secondary biliary cirrhosis, primary or secondary sclerosing cholangitis,
             hepatic sarcoidosis, or other cholestatic disorders

          -  Subjects unable to perform the MBT within 7 days of HVPG procedure.

          -  Subject should not have taken any of the following for at least 48 hours prior to the
             breath test: Acyclovir , allopurinol, amiodarone, carbamazepine, cimetidine,
             ciprofloxacin, daidzein, (herbal) disulfiram, echinacea, enoxacin, famotidine,
             fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine,
             phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil,
             zileuton or oral contraceptives or any medication that might interfere with Methacetin
             metabolism or might affect CYP 1A2

          -  Subject should not have taken amiodarone or statins within the last 30 days prior to
             the breath test or HVPG procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Carlos Garcia Pagan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avraham Hershkowitz, MSc</last_name>
    <phone>+972-8-9737513</phone>
    <email>avrahamh@exalenz.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Connecticut HealthCare System</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>(University of Barcelona) Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Sáez Carceller</last_name>
      <phone>34 93 2275400</phone>
      <email>RMSAEZ@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Garcia Pagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina M Martin</last_name>
      <phone>+34 913368592</phone>
      <email>mcrismartin@terra.com</email>
    </contact>
    <investigator>
      <last_name>Agustin Albillos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MBT</keyword>
  <keyword>CSPH</keyword>
  <keyword>HVPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

